The second-largest private sector lender ICICI Bank on Monday launched a new version of its mobile payment app which is interoperable and allows payments and other banking services to customers of any other bank.
The latest version of the bank”s mobile banking app is called iMobile Pay, through which customers of other banks can link their bank account, generate a UPI ID and start paying, shopping, transfer funds to any bank account or to any other payment apps or digital wallets; or bill payments and online recharges, among others, ICICI Bank said in a statement.
The app also offers instant banking services such as savings account, investments, loans, credit cards, gift cards, and travel cards, among others.
Claiming it to be a first-of-its-kind facility, the bank said the app also provides interoperability as customers no longer have to remember the UPI IDs of their contacts and can transfer money across payment apps and wallets.
“We have always been at the forefront of introducing pioneering innovations, including the country’s first mobile banking app, iMobile, in 2008. With the new version of the app, a customer of any other bank can link all their bank accounts to this app even as they bank with any bank,” the statement said.
Mean-while, India recorded 32,981 new COVID-19 cases in the last 24 hours, taking the total number of active coronavirus cases in the country to 3,96,729, said the Union Ministry of Health and Family Welfare on Monday. With 39,109 new recoveries, the number of overall recovered COVID-19 patients stands at 91,39,901, pushing the recovery rate to 94.37 percent today.
The overall COVID-19 cases reached 96,77,203, including 3,96,729 active cases and 91,39,901 recoveries. With 391 new deaths, the cumulative toll mounted to 1,40,573.
Also, the Serum Institute of India, the world’s largest vaccine maker by the number of doses produced, has sought government approval for emergency use authorization of the coronavirus vaccine that it is developing with the University of Oxford and British drugmaker AstraZeneca, sources have said.